Skip to search formSkip to main contentSkip to account menu

efonidipine

Known as: 3-Pyridinecarboxylic acid, 5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(phenyl(phenylmethyl)amino)ethyl ester, P-oxide, monohydrochloride, 5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylic acid, 2-(phenyl(phenylmethyl)amino) ethyl ester, P-oxide, hydrochloride 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Aim:  The T‐type calcium channel is expressed in vascular endothelial cells, but its role in endothelial cell function is yet to… 
2007
2007
To prevent cardiovascular disease, targeting aldosterone synthesis and release may be clinically important. Aldosterone… 
2007
2007
Efonidipine, a dihydropirydine calcium channel blocker, has been shown to dilate the efferent glomerular arterioles as… 
2006
2006
Targeting aldosterone synthesis and/or release represents a potentially useful approach to the prevention of cardiovascular… 
2006
2006
Efonidipine can block both L- and T- type Ca2+ channels. In a previous in vitro study, we clarified that efonidipine dramatically… 
Highly Cited
2004
Highly Cited
2004
Efonidipine, a derivative of dihydropyridine Ca2+ antagonist, is known to block both L‐ and T‐type Ca2+ channels. It remains to… 
Highly Cited
2001
Highly Cited
2001
Although calcium antagonists exert preferential vasodilation of renal afferent arterioles, we have recently demonstrated that… 
1998
1998
We investigated the effects of a calcium antagonist, efonidipine, which was reported to dilate not only afferent arterioles but…